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Disease awareness advertising: women's intentions following exposure
Abstract
Background: In Australia, where direct to consumer advertising of prescription medicines is prohibited,
pharmaceutical companies can sponsor disease awareness advertising targeting consumers. This study
examined the impact of disease awareness advertising exposure on older women's reported behavioural
intentions. Method: Women were approached in a shopping centre and randomly assigned mock
advertisements for two health conditions. Disease information and sponsors were manipulated. Results:
Two hundred and forty-one women responded to 466 advertisements. Almost half reported an intention
to ask their doctor for a prescription or referral as a result of seeing the advertisement, but more reported
they would talk to their doctor and ask about treatments and tests. Participants were more likely to report
an intention to ask for prescriptions if they perceived the health condition to be severe and themselves
susceptible or if they had viewed advertisements containing limited information on the disease.
Discussion: Disease awareness advertising may stimulate demand for prescription medicine products.
This has serious implications for general practitioners and regulators
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Disease awareness advertising
Danika Hall
Sandra Jones
Don Iverson

Women’s intentions following exposure

Background
In Australia, where direct to consumer
advertising of prescription medicines is
prohibited, pharmaceutical companies
can sponsor disease awareness
advertising targeting consumers. This
study examined the impact of disease
awareness advertising exposure on
older women’s reported behavioural
intentions.

Method
Women were approached in a
shopping centre and randomly
assigned mock advertisements for two
health conditions. Disease information
and sponsors were manipulated.

Results
Two hundred and forty-one women
responded to 466 advertisements.
Almost half reported an intention to ask
their doctor for a prescription or referral
as a result of seeing the advertisement,
but more reported they would talk to
their doctor and ask about treatments
and tests. Participants were more
likely to report an intention to ask for
prescriptions if they perceived the health
condition to be severe and themselves
susceptible or if they had viewed
advertisements containing limited
information on the disease.

Discussion
Disease awareness advertising may
stimulate demand for prescription
medicine products. This has serious
implications for general practitioners
and regulators.
Keywords: doctor-patient relations;
education, health (to lay people); public
health policy; public health

There is growing concern from advisory
and advocacy groups in Australia, as
well as in other countries, regarding the
influence of the pharmaceutical industry
on the prescribing habits of doctors.1,2
Concern has centred around marketing
practices that directly influence doctors’
prescribing behaviour,3,4 as well as
pharmaceutical promotions that directly
target consumers.5,6
While direct-to-consumer advertising (DTCA)
of prescription medicines is illegal in Australia,
pharmaceutical companies are allowed to engage
in disease awareness advertising (DAA) via a
range of media. Disease awareness advertising
in Australia is currently regulated by the industry
body Medicines Australia. Edition 16 of the Code
of Conduct recently came into effect with a specific
section (Section 12.7) on ‘Disease education
activities in any media’.7 The guidelines state
that advertisements cannot include the name of
a specific prescription medicine but may include
disease information such as the symptoms and
prevalence of a disease.7
	International research into the effects of DAA
demonstrate that it can increase consultation
rates as well as prescriptions for the advertiser’s
product.8,9 A recent survey of Australian general
practitioners10 reported in the popular medical
press found a pharmaceutical mass media
campaign coincided with increased patient
requests about the advertiser’s product.
Disease awareness advertising has been
labelled as disease mongering – ‘widening
boundaries of treatable illness in order to expand
markets for those who profit from treatments’.3
Disease awareness advertising has been criticised
for promoting health conditions with vague
or nonspecific symptoms, or exaggerating the
prevalence of a condition and using fear appeals,

such that consumers are encouraged to identify
themselves as having the condition or being at
greater risk of contracting it.1 While DAA can be
eye catching and emotive, it often provides very
limited disease information,11 which is the same
criticism received by DTCA.12
	The pharmaceutical industry, and its
proponents, argue that advertising to consumers
provides education about health conditions
and treatment options, and can assist in earlier
diagnosis and treatment, improved patientdoctor relationships, and enhanced medication
compliance.13,14 There is also the argument of
the potential for the pharmaceutical industry
to advertise conditions that have high levels of
underdiagnosis such as diabetes.15
	The purpose of this study was to determine the
impact of DAA on the behavioural intentions of
older Australian women, including their intention
to seek further information, and/or request a
prescription or referral from their doctor. The study
also examined perceptions of the severity of,
and their susceptibility to, two advertised health
conditions.

Method
The study design included the development of mock
magazine advertisements for two health conditions
(Figure 1). Women were selected as the target
group as they have higher magazine readership in
Australia and generally have greater involvement
in seeking health information and making health
decisions. The age range of 45 years or over was
chosen to facilitate the selection of targeted health
conditions for the advertisement stimuli.
	The health conditions were osteopaenia, which
is a state of early bone loss that can potentially
increase the risk of developing osteoporosis;16
and fibromyalgia, which is thought to be a
disorder of the central nervous system associated
with intensified pain due to abnormal sensory
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Forget about future fractures.
Are you over 60 or post-menopausal with a family history
of osteoporosis?
It may be that you have osteopenia or early bone loss which
can increase your risk of developing osteoporosis and
future bone fractures.
To see if you have osteopenia you need to take a bone density test,
available at many pharmacies. If your bone density test score is low
then you should talk with your doctor.
Your doctor can advise about new and effective medicines to treat
osteopenia that help prevent the onset of osteoporosis.

For more information visit www.osteopenia.com.au
or call 1800 001 002.
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ZUERST Pharmaceuticals.
Zuerst Pharmaceuticals Pty. Ltd. ABN 95 000 180 999. Unit 32 Times Square Industrial Park, Point Cook VIC 3030.

Understanding Osteopenia...
Osteopenia is a state of early bone loss which can increase your risk of
developing osteoporosis and future bone fractures.
It is of particular concern if you are over 60 years of age or
post-menopausal with a family history of osteoporosis.
What is Osteopenia?
Osteopenia is a condition that describes lower bone mass and is a state which may
precede osteoporosis. There are no obvious symptoms for osteopenia. Women over 60
years of age, and post-menopausal women with a family history of osteoporosis are at
greater risk.
What is Osteoporosis?
Osteoporosis is a disease in which the density and quality of bone are reduced, leading
to bone weakness and increased risk of fracture, particularly of the spine, wrist and hip.
Two million Australians are affected by osteoporosis, and every 8 minutes someone is
admitted to hospital with a fracture.
Diagnosis and Management of Osteopenia
Women at risk of osteopenia can arrange for a bone-density test through their doctor or
other health provider to determine their bone density score. If they have osteopenia then
there are a range of ways to manage the condition including increasing calcium intake
and increasing strength-building exercise.
Treatment
Women with osteopenia can talk to their doctor about new and effective medicines
which restore minerals to bones and help prevent the onset of osteoporosis.

For more information go to www.osteopenia.com.au
or call 1800 001 002.
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FOUNDATION
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Figure 1. Mock magazine advertisements for osteoporosis and osteopenia

processing.17 Both conditions have been subject
to controversy regarding their clinical importance,
and there is concern that they may attract disease
mongering.18,19 The authors were not able to find
evidence of education or promotion targeting
consumers about these conditions in Australia.
	There are three potential prescription medicine
categories for the prevention of osteoporosis
in postmenopausal women, and Australian
clinical guidelines recommend the use of two
of these for reducing the risk of osteoporotic
fractures by increasing bone mineral density in
postmenopausal women at risk.20 It is therefore
feasible that pharmaceutical companies would
sponsor Australian awareness advertising about
osteopaenia to encourage women to undertake
bone density testing and preventive treatment,
as has occurred in the United States of America
(USA).19,21
	There are no specific Australian guidelines
for diagnosis or management of fibromyalgia,
although the American College of Rheumatology
classification criteria are commonly used.22 There
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is some evidence for treatment with prescription
medicines including amitriptyline, fluoxetine as
well as serotonin and norepinephrine reuptake
inhibitors; however, a multidisciplinary approach
including patient education is recommended.22
Prescription medicine advertising for the treatment
of fibromyalgia (eg. pregabalin) has occurred in the
USA;18 the growing recognition of the condition in
Australia suggests it could be a target country for
disease advertising by pharmaceutical companies.
	The mock advertisements included similar
images and quantity of text as is found in current
DAA in Australian magazines.12 Two different
manipulations were applied to the advertisements:
the amount of information provided and the
sponsor logos. For the information manipulation,
participants received either limited information
(brief descriptions of the symptoms, and how
to seek further information) or more detailed
information (fuller descriptions of the symptoms,
causation, diagnosis and management as well as
how to seek further information). For the sponsor
manipulation, fictional logos at the bottom of

the advertisement varied between nonprofit,
pharmaceutical company and a combination of
these two (cosponsored).
Research assistants approached women in a
commercial shopping centre in the Wollongong
(New South Wales) metropolitan area during retail
hours over 5 consecutive days in November 2008.
Refusals and ineligible respondents were recorded.
	Consenting participants were randomly
assigned an advertisement for one health condition
and then received an advertisement for the other
health condition with the same sponsor and with
information manipulation. Participants viewed the
advertisements and completed the questionnaires
independently and were debriefed regarding the
hypothetical nature of the advertisements.
	This study was approved by The University of
Wollongong Human Research Ethics Committee.
A score was created for perceived severity of
the condition, which included responses to three
bipolar adjective scales for how ‘distressing,
serious and inconvenient’ it would be to experience
the condition. Cronbach’s alpha for the three item
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scale was 0.822, indicating an appropriate level
of internal consistency. Data was analysed with
SPSS V15. Descriptive analysis was conducted and
nonparametric tests were used as the data was not
normally distributed.23

Results
A total of 977 women were approached to
participate in the study, with 30% agreeing.
However, only 82.5% of those who agreed were
eligible. A total of 241 women aged 48–85 years
(median age 64) participated in the survey. The
demographic profile of participants was similar
to women in this age group in the Wollongong
local government area and Australian census data
(except that a greater proportion of participants
in the study had higher levels of educational
attainment).
Questionnaires were completed for a total of
466 advertisements: 232 on fibromyalgia and 234
on osteopaenia, and most participants rated the
advertisements as easy to understand. Only 36%
of participants agreed that they or someone they
knew well had suffered from fibromyalgia, but 64%
agreed that they or someone they knew well had
suffered from osteopaenia.

Behavioural intentions
Forty-nine percent of the participants agreed that
they would ask their doctor for a prescription or
referral as a result of seeing the advertisement,
and the majority agreed that they would take other
actions (Table 1).
	Contingency table analysis indicated a
statistically different result between reported
behavioural intentions for the two different health
conditions: participants viewing the advertisement
for osteopaenia were more likely to report an
intention to talk to their doctor about the condition
(p=0.029) and to ask their doctor about treatments
or tests (p=0.024) (Table 2).
Behavioural intentions did not differ significantly
between the sponsor manipulations. Participants
who viewed low information advertisements were
more likely to report an intention to ask their doctor
for a prescription or a referral (p=0.036) than those
who viewed high information advertisements (Table
3). Mann-Whitney U tests showed that participants
who intended to ask for a prescription or referral
were more likely to be older (p<0.001), and less
educated (p<0.001).

	If the participant or someone they knew well had
suffered from the advertised health condition then
they were significantly more likely to agree that they
would take action compared with those without
personal experience of the condition (Table 4). This
was particularly the case for intention to ask for a
prescription or referral, with 57.3% of participants
with personal experience reporting this intention
compared with 39.3% of those without (p<0.001).

Perceived severity and susceptibility
Participants perceived both conditions to be severe
(mean score of 4.53 for fibromyalgia and 4.42 for
osteopaenia on a six point scale). There was no
significant difference between scores for the two
conditions. When asked to rate how likely it would
be that they would experience the advertised
conditions (on a six point scale), participants
perceived themselves to be susceptible to both
conditions (mean score of 3.40 for fibromyalgia
and 3.88 for osteopaenia) but significantly more
susceptible to osteopaenia (p=0.007). Just over 25%

of participants estimated that it was very likely that
they would experience fibromyalgia in the future,
whereas 36% estimated that it was very likely that
they would experience osteopaenia. Participants
who nominated an intention to ask their doctor for
a prescription or a referral were significantly more
likely to perceive higher susceptibility to the health
conditions (mean score 4.14 compared with 3.12
for participants who did not intend to ask: p<0.001)
and have higher severity scores (mean score of 4.77
compared with 4.28: p<0.001).

Discussion
Participants who viewed the advertisements
with less disease information were more likely
to express an intention to ask their doctor for a
prescription or a referral. This finding may concern
GPs as it indicates the potential for industry DAA
to stimulate patient requests for prescription
medicines – this has been found in overseas
studies of DAA.8,9 Such requests may cause
tension in patient-doctor relationships and valuable

Table 1. Behavioural intention by advertisement
Behavioural intention

Percentage – including all
advertisements (n=466)

As a result of seeing this advertisement would you…?
Talk to your doctor about the condition

77%

Ask your doctor about treatments or tests

73%

Look for information as directed by the advertisement

64%

Look for information from other sources

55%

Ask your doctor for a prescription or a referral

49%

Do nothing

23%

Table 2. Behavioural intention by condition type

c2

Behavioural intention

Condition type

As a result of seeing this
advertisement would you…?

Fibromyalgia
(n=232)

Osteopenia
(n=234)

p value

Talk to your doctor about the
condition

73.1%

81.7%

0.029

Ask your doctor about treatments
or tests

68.3%

77.8%

0.024

Look for information as directed by
the advertisement

63.1%

65.5%

0.596

Look for information from other
sources

55.0%

55.5%

0.916

Ask your doctor for a prescription
or a referral

45.1%

52.5%

0.123

Do nothing

25.0%

20.6%

0.291
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Table 3. Behavioural intention by information manipulation
Behavioural intention

Information level

c2

As a result of seeing this advertisement would you…?

High
(n=110)

Low
(n=356)

p value

Talk to your doctor about the condition

73.8%

78.5%

0.311

Ask your doctor about treatments or tests

66.7%

75.0%

0.092

Look for information as directed by the advertisement

58.5%

66.1%

0.155

Look for information from other sources

48.1%

57.4%

0.092

Ask your doctor for a prescription or a referral

39.8%

51.7%

0.036

Do nothing

25.8%

21.9%

0.432

Table 4. Behavioural intention by personal experience
With personal
experience

Without personal
experience

c2 p value

83.1%

71.4%

0.004

Ask your doctor about treatments
or tests

77.9%

68.1%

0.022

Look for further information as
directed by the advertisement

69.0%

58.8%

0.028

Look for further information from
other sources

61.4%

49.1%

0.010

Ask your doctor for a prescription
or referral

57.3%

39.3%

0.000

Do nothing

16.8%

28.6%

0.006

Behavioural intention
As a result of seeing this
advertisement would you…?
Talk to your doctor about the
condition

consultation time may be spent re-educating
patients, as has been found for DTCA.24 A recent
survey found that the majority of Australian GPs
who received patient requests about a medication
as a result of DAA were opposed to these
advertising campaigns.10
	The results have important implications for
regulation in Australia as they indicate that DAA
can stimulate patients’ intention to make requests
to doctors for prescription medicine products,
particularly if limited disease information is
provided. While the effect of the more specific
guidelines for DAA in Medicines Australia’s Code
of Conduct, edition 16 are yet to be determined,
regulators should provide more guidance to
advertisers regarding types of disease information
and the level of detail that should be provided.
More prescriptive guidelines are provided in other
countries such as the United Kingdom.25
Just over one-quarter of participants estimated
that it was very likely that they would experience
fibromyalgia in the future, whereas international
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data suggests that 2–10% of women have the
condition.26 Similarly, 36% estimated that it was
very likely that they would experience osteopaenia,
however, an Australian study of women aged
over 50 years found a prevalence of 15%.27 While
participants were not asked about their perceived
susceptibility to the conditions before being shown
the stimuli, the results suggest that providing more
detailed prevalence and risk factor information
in DAA may help consumers to more accurately
identify their susceptibility. Participants that
reported an intention to ask for a prescription or
referral perceived a higher level of susceptibility
to, and severity of, the health conditions. These
results provide some support for the argument
that DAA can be seen as disease mongering and
can inflate perceptions of the prevalence of the
advertised disease.3

Study limitations
A limitation of this study is that participants’
involvement with the stimuli would be different to

how they would view magazine advertisements in
a ‘real life’ context. Further research is required to
determine whether reported intentions to speak
with GPs and request a prescription or referral
articulate into actual behaviour.
	Other limitations include sampling by intercept
method which attracts a level of response bias
and results may not be representative of all
Australian women in this age group. Due to the
limited nature and size of the sample, the findings
should be interpreted with caution and may not
be generalisable to the Australian population. It is
possible that participants confused the advertised
condition ‘osteopaenia’ with the better known
condition ‘osteoporosis’. This may have led to a
greater perceived severity and susceptibility to
the condition, increased agreement for personal
experience with the condition, and intention to
take action.
Further studies are required with true DAA for
a range of health conditions, utilising larger and
more representative samples to confirm these
results. However, results of this study indicate
the potential for DAA to influence patients to
request prescription medicine or a referral from
their doctor. In the current study, the effects were
most pronounced in older, less educated women,
along with those reporting personal experience
with the health condition and those viewing
advertisements with limited disease information.
Medicines Australia has the opportunity to provide
more detailed guidance regarding the amount
and types of disease information to be included
in industry DAA to help ensure it is of greater
educational value, and does not serve as a method
of stimulating demand for prescription medicines.
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